{ "instance": { "dawn-20220630.htm": { "axisCustom": 3, "axisStandard": 21, "contextCount": 235, "dts": { "calculationLink": { "local": [ "dawn-20220630_cal.xml" ] }, "definitionLink": { "local": [ "dawn-20220630_def.xml" ] }, "inline": { "local": [ "dawn-20220630.htm" ] }, "labelLink": { "local": [ "dawn-20220630_lab.xml" ] }, "presentationLink": { "local": [ "dawn-20220630_pre.xml" ] }, "schema": { "local": [ "dawn-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 534, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 11, "http://xbrl.sec.gov/dei/2022": 4, "total": 15 }, "keyCustom": 49, "keyStandard": 223, "memberCustom": 36, "memberStandard": 28, "nsprefix": "dawn", "nsuri": "http://www.dayonebio.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Cover Page", "role": "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Summary Of Significant Accounting Policies", "role": "http://www.dayonebio.com/20220630/taxonomy/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary Of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Recurring Fair Value Measurements", "role": "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurements", "shortName": "Recurring Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Balance Sheet Items", "role": "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItems", "shortName": "Balance Sheet Items", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Significant Agreements", "role": "http://www.dayonebio.com/20220630/taxonomy/role/SignificantAgreements", "shortName": "Significant Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Commitments and Contingencies", "role": "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "dawn:TemporaryEquityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Redeemable Convertible Preferred Shares", "role": "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredShares", "shortName": "Redeemable Convertible Preferred Shares", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "dawn:TemporaryEquityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Common Stock", "role": "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStock", "shortName": "Common Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Equity-Based Compensation", "role": "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensation", "shortName": "Equity-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Net Loss Per Share", "role": "http://www.dayonebio.com/20220630/taxonomy/role/NetLossPerShare", "shortName": "Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "dawn:RedeemableNonControllingInterestTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Redeemable NonControlling Interest", "role": "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableNoncontrollingInterest", "shortName": "Redeemable NonControlling Interest", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "dawn:RedeemableNonControllingInterestTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_13ddd3af-6ff6-40e3-8de9-6a40afe62e01", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_13ddd3af-6ff6-40e3-8de9-6a40afe62e01", "decimals": "-3", "lang": null, "name": "us-gaap:MarketableSecurities", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Defined Contribution Plan", "role": "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDefinedContributionPlan", "shortName": "Defined Contribution Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Subsequent Event", "role": "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureSubsequentEvent", "shortName": "Subsequent Event", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Recurring Fair Value Measurement (Tables)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementTables", "shortName": "Recurring Fair Value Measurement (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "dawn:ScheduleOfPrepaidAndOtherCurrentAssetstableTextBlockTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Balance Sheet Items (Tables)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsTables", "shortName": "Balance Sheet Items (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "dawn:ScheduleOfPrepaidAndOtherCurrentAssetstableTextBlockTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "dawn:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Common Stock (Tables)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockTables", "shortName": "Common Stock (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "dawn:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Equity-Based Compensation (Tables)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationTables", "shortName": "Equity-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Net Loss Per Share (Tables)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/NetLossPerShareTables", "shortName": "Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_7f2125bf-d6cf-4584-b5c6-64be679ecbb7", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Description of Business and Organization - Additional Information (Detail)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail", "shortName": "Description of Business and Organization - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_7f2125bf-d6cf-4584-b5c6-64be679ecbb7", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_13ddd3af-6ff6-40e3-8de9-6a40afe62e01", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_fb1ac982-c075-42bb-8849-f8700d72f178", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Recurring Fair Value Measurement - Summary of Company's Financial Instruments (Detail)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementSummaryOfCompanysFinancialInstrumentsDetail", "shortName": "Recurring Fair Value Measurement - Summary of Company's Financial Instruments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_fb1ac982-c075-42bb-8849-f8700d72f178", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_697559c8-883b-4ec7-b193-07416b16ce19", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Recurring Fair Value Measurement - Schedule of cash equivalents, marketable securities, and unrealized gains and losses (Details)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails", "shortName": "Recurring Fair Value Measurement - Schedule of cash equivalents, marketable securities, and unrealized gains and losses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_697559c8-883b-4ec7-b193-07416b16ce19", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "dawn:ScheduleOfAvailableForSaleMarketableSecuritiesWithGrossUnrealizedLossesTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_13ddd3af-6ff6-40e3-8de9-6a40afe62e01", "decimals": "-3", "first": true, "lang": null, "name": "dawn:AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Recurring Fair Value Measurement - Schedule of available-for-sale marketable securities with gross unrealized losses (Details)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails", "shortName": "Recurring Fair Value Measurement - Schedule of available-for-sale marketable securities with gross unrealized losses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "dawn:ScheduleOfAvailableForSaleMarketableSecuritiesWithGrossUnrealizedLossesTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_13ddd3af-6ff6-40e3-8de9-6a40afe62e01", "decimals": "-3", "first": true, "lang": null, "name": "dawn:AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "dawn:ScheduleOfMaturitiesOfOurAvailableForSaleMarketableSecuritiesTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_13ddd3af-6ff6-40e3-8de9-6a40afe62e01", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Recurring Fair Value Measurement - Schedule of maturities of available-for-sale marketable securities (Details)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesOfAvailableforsaleMarketableSecuritiesDetails", "shortName": "Recurring Fair Value Measurement - Schedule of maturities of available-for-sale marketable securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "dawn:ScheduleOfMaturitiesOfOurAvailableForSaleMarketableSecuritiesTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_13ddd3af-6ff6-40e3-8de9-6a40afe62e01", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Recurring Fair Value Measurement - Additional Information (Detail)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementAdditionalInformationDetail", "shortName": "Recurring Fair Value Measurement - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "dawn:ScheduleOfPrepaidAndOtherCurrentAssetstableTextBlockTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_13ddd3af-6ff6-40e3-8de9-6a40afe62e01", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Balance Sheet Items - Summary of Prepaid and Other Current Assets (Detail)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPrepaidAndOtherCurrentAssetsDetail", "shortName": "Balance Sheet Items - Summary of Prepaid and Other Current Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "dawn:ScheduleOfPrepaidAndOtherCurrentAssetstableTextBlockTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_13ddd3af-6ff6-40e3-8de9-6a40afe62e01", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_13ddd3af-6ff6-40e3-8de9-6a40afe62e01", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Balance Sheet Items - Summary of Property and Equipment (Detail)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentDetail", "shortName": "Balance Sheet Items - Summary of Property and Equipment (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_13ddd3af-6ff6-40e3-8de9-6a40afe62e01", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_13ddd3af-6ff6-40e3-8de9-6a40afe62e01", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedPayrollTaxesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Balance Sheet Items - Summary of Accrued expenses and other current liabilities (Detail)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail", "shortName": "Balance Sheet Items - Summary of Accrued expenses and other current liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_13ddd3af-6ff6-40e3-8de9-6a40afe62e01", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedPayrollTaxesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_8b9070f1-66a5-4d8d-8bb4-f864968844b3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Significant Agreements - Additional Information (Detail)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/SignificantAgreementsAdditionalInformationDetail", "shortName": "Significant Agreements - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_c0192e0c-e7ae-4511-8190-5c6606e553ab", "decimals": "-5", "lang": null, "name": "dawn:UpfrontOfCashPayment", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_13ddd3af-6ff6-40e3-8de9-6a40afe62e01", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Commitment and Contingencies - Summary of Future Lease Obligations (Detail)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesSummaryOfFutureLeaseObligationsDetail", "shortName": "Commitment and Contingencies - Summary of Future Lease Obligations (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_13ddd3af-6ff6-40e3-8de9-6a40afe62e01", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_686f2700-0390-44a5-84c6-8af24d010e3e", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070 - Statement - Condensed Consolidated Statements of Operations (unaudited)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "shortName": "Condensed Consolidated Statements of Operations (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_686f2700-0390-44a5-84c6-8af24d010e3e", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Commitment and Contingencies - Additional Information (Detail)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesAdditionalInformationDetail", "shortName": "Commitment and Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:LossContingencyAccrualAtCarryingValue", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_2a4e4b49-a603-471c-9dbe-1a5109e2290d", "decimals": "-3", "lang": null, "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_7f2125bf-d6cf-4584-b5c6-64be679ecbb7", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Redeemable Convertible Preferred Shares - Additional Information (Detail)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail", "shortName": "Redeemable Convertible Preferred Shares - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "dawn:TemporaryEquityTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_264e3492-5c8b-4025-a621-d0299209d11b", "decimals": "INF", "lang": null, "name": "dawn:CommonStockSharesIssuedAsAResultOfConversionOfTemporaryEquityIntoPermanentEquity", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_13ddd3af-6ff6-40e3-8de9-6a40afe62e01", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Common Stock - Additional Information (Detail)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "shortName": "Common Stock - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_b46f28f9-c25d-491a-9403-c7df47b6e20d", "decimals": "0", "lang": null, "name": "dawn:NumberOfDirectorsEntitledToBeElectedByTheHoldersOfCommonStock", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "dawn:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_13ddd3af-6ff6-40e3-8de9-6a40afe62e01", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Common Stock - Schedule of Common Stock Shares Reserved for Future Issuance (Details) (Details)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails", "shortName": "Common Stock - Schedule of Common Stock Shares Reserved for Future Issuance (Details) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "dawn:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_d3ad9f07-8248-46a4-8ea4-d6d699bf5306", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "dawn:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_13ddd3af-6ff6-40e3-8de9-6a40afe62e01", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Equity-Based Compensation - Additional Information (Detail)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail", "shortName": "Equity-Based Compensation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_38816bf7-edc4-4833-bbbe-481f4fd878db", "decimals": "2", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_df8e9c77-8b61-45b2-b3c0-afb47eef17e1", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Equity-Based Compensation - Summary of Fair Value of The Incentive Shares Estimated Using An Option Pricing Model (Detail)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail", "shortName": "Equity-Based Compensation - Summary of Fair Value of The Incentive Shares Estimated Using An Option Pricing Model (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_1602accd-7184-4286-83ae-9178e4b67426", "decimals": "2", "lang": null, "name": "dawn:ParticipatingThreshold", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_f03ee9e2-c21c-45f5-be88-d10771ad436f", "decimals": "INF", "first": true, "lang": null, "name": "dawn:ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Equity-Based Compensation - Summary of The Unvested Common Stock (Detail)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheUnvestedCommonStockDetail", "shortName": "Equity-Based Compensation - Summary of The Unvested Common Stock (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_f03ee9e2-c21c-45f5-be88-d10771ad436f", "decimals": "INF", "first": true, "lang": null, "name": "dawn:ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Equity-Based Compensation - Summary of Stock Option Activity Under The 2021 Plan (Detail)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityUnderThe2021PlanDetail", "shortName": "Equity-Based Compensation - Summary of Stock Option Activity Under The 2021 Plan (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_d118fff9-e7af-4783-9a21-578cfdaab2d3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Equity-Based Compensation - Summary of Restricted Stock Units Activity (Detail)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitsActivityDetail", "shortName": "Equity-Based Compensation - Summary of Restricted Stock Units Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_63ad7dec-5d9b-4933-9a1e-ebcad640cf0f", "decimals": "INF", "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_cf549cee-37f4-44d7-978c-54752b491617", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Equity-Based Compensation - Fair value of our common stock to be issued under the ESPP (Details)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationFairValueOfOurCommonStockToBeIssuedUnderTheEsppDetails", "shortName": "Equity-Based Compensation - Fair value of our common stock to be issued under the ESPP (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_cf549cee-37f4-44d7-978c-54752b491617", "decimals": "4", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_686f2700-0390-44a5-84c6-8af24d010e3e", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100080 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited", "shortName": "Condensed Consolidated Statements of Comprehensive Loss (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_686f2700-0390-44a5-84c6-8af24d010e3e", "decimals": "-3", "lang": null, "name": "us-gaap:ComprehensiveIncomeNetOfTax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "dawn:ScheduleOfStockOptionsAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_078f7517-dd4b-4524-b132-e3a8c229ee98", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Equity-Based Compensation - Summary of The Black-Scholes Option Pricing Model to Estimate The Fair Value of Stock Option Granted (Detail)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail", "shortName": "Equity-Based Compensation - Summary of The Black-Scholes Option Pricing Model to Estimate The Fair Value of Stock Option Granted (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "dawn:ScheduleOfStockOptionsAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_078f7517-dd4b-4524-b132-e3a8c229ee98", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "dawn:ScheduleOfPerformanceStockOptionsAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_38816bf7-edc4-4833-bbbe-481f4fd878db", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Equity-Based Compensation - Summary of The Black-Scholes Option Pricing Model to Estimate The Fair Value of Performance Stock Op (Details)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails", "shortName": "Equity-Based Compensation - Summary of The Black-Scholes Option Pricing Model to Estimate The Fair Value of Performance Stock Op (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "dawn:ScheduleOfPerformanceStockOptionsAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_38816bf7-edc4-4833-bbbe-481f4fd878db", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_686f2700-0390-44a5-84c6-8af24d010e3e", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Equity-Based Compensation - Summary of Share/Stock-based Compensation Expense Recorded in The Accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss (Detail)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfSharestockbasedCompensationExpenseRecordedInTheAccompanyingCondensedConsolidatedStatementsOfOperatio", "shortName": "Equity-Based Compensation - Summary of Share/Stock-based Compensation Expense Recorded in The Accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_46af917b-306e-40e4-b0cc-10ecc0fe9b17", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_686f2700-0390-44a5-84c6-8af24d010e3e", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100590 - Disclosure - Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share Attributable to Common Shareholders/Stockholders (Detail)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersStockholdersDetail", "shortName": "Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share Attributable to Common Shareholders/Stockholders (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_686f2700-0390-44a5-84c6-8af24d010e3e", "decimals": "-3", "lang": null, "name": "us-gaap:NetIncomeLossAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100600 - Disclosure - Net Loss Per Share - Summary of Outstanding Potentially Dilutive Securities Have Been Excluded From Calculation of Diluted Net Loss Per Share (Detail)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/NetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesHaveBeenExcludedFromCalculationOfDilutedNetLossPerShareDetail", "shortName": "Net Loss Per Share - Summary of Outstanding Potentially Dilutive Securities Have Been Excluded From Calculation of Diluted Net Loss Per Share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_686f2700-0390-44a5-84c6-8af24d010e3e", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100610 - Disclosure - Redeemable NonControlling Interest - Additional Information (Detail)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableNoncontrollingInterestAdditionalInformationDetail", "shortName": "Redeemable NonControlling Interest - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "dawn:RedeemableNonControllingInterestTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_8ef6bbd5-b942-4caa-b9f5-6d5271d6c8fe", "decimals": "-5", "lang": null, "name": "dawn:AdjustmentToAdditionalPaidInCapitalLossOnConversionOfTemporaryEquityIntoPermanentEquity", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DefinedContributionPlanTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_686f2700-0390-44a5-84c6-8af24d010e3e", "decimals": "-5", "first": true, "lang": null, "name": "dawn:DefinedContributionPlanEmployerMatchingContribution", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100620 - Disclosure - Defined Contribution Plan (Additional Information) (Details)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails", "shortName": "Defined Contribution Plan (Additional Information) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DefinedContributionPlanTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_686f2700-0390-44a5-84c6-8af24d010e3e", "decimals": "-5", "first": true, "lang": null, "name": "dawn:DefinedContributionPlanEmployerMatchingContribution", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_30abb472-4f4f-47a8-9d3b-ba92b0e6a0da", "decimals": "-5", "first": true, "lang": null, "name": "dawn:PaymentOfMilestones", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100630 - Disclosure - Subsequent Event (Additional Information) (Details)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "shortName": "Subsequent Event (Additional Information) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_30abb472-4f4f-47a8-9d3b-ba92b0e6a0da", "decimals": "-5", "first": true, "lang": null, "name": "dawn:PaymentOfMilestones", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_0cf0f0b4-4c74-4863-9a6e-e294b2bff321", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100090 - Statement - Condensed Consolidated Statements of Redeemable Convertible Preferred Shares, Redeemable Noncontrolling Interest and Stockholders' Equity/ Members' (Deficit) (unaudited)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic", "shortName": "Condensed Consolidated Statements of Redeemable Convertible Preferred Shares, Redeemable Noncontrolling Interest and Stockholders' Equity/ Members' (Deficit) (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_140d2827-07de-4941-b1f8-cb61ca9f68f6", "decimals": "0", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_e9ae5769-d9f3-45eb-ae36-148088b1cb86", "decimals": "-3", "first": true, "lang": null, "name": "dawn:StockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100100 - Statement - Condensed Consolidated Statements of Redeemable Convertible Preferred Shares, Redeemable Noncontrolling Interest and Stockholders' Equity/ Members' (Deficit) (Parenthetical) (unaudited)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic1", "shortName": "Condensed Consolidated Statements of Redeemable Convertible Preferred Shares, Redeemable Noncontrolling Interest and Stockholders' Equity/ Members' (Deficit) (Parenthetical) (unaudited)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_e9ae5769-d9f3-45eb-ae36-148088b1cb86", "decimals": "-3", "first": true, "lang": null, "name": "dawn:StockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100110 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)", "role": "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": "-3", "lang": null, "name": "us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Description of Business and Organization", "role": "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganization1", "shortName": "Description of Business and Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dawn-20220630.htm", "contextRef": "C_a3963689-a45d-4e73-92f7-fab162794312", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 71, "tag": { "dawn_AccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounting Policies LineItems.", "label": "Accounting Policies [Line Items]" } } }, "localname": "AccountingPoliciesLineItems", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "dawn_AccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounting Policies Table.", "label": "Accounting Policies [Table]" } } }, "localname": "AccountingPoliciesTable", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "dawn_AccruedResearchAndDevelopmentExpenses": { "auth_ref": [], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 0.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Research and Development Expenses.", "label": "Accrued research and development expenses", "terseLabel": "Accrued research and development expenses" } } }, "localname": "AccruedResearchAndDevelopmentExpenses", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "dawn_AdditionalNumberOfCommonStockSharesReservedForFutureIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional number of common stock shares reserved for future issuance.", "label": "Additional Number Of Common Stock Shares Reserved For Future Issuance", "terseLabel": "Additional number of common stock shares reserved for future issuance" } } }, "localname": "AdditionalNumberOfCommonStockSharesReservedForFutureIssuance", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "dawn_AdjustmentToAdditionalPaidInCapitalLossOnConversionOfTemporaryEquityIntoPermanentEquity": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustment to additional paid in capital loss on conversion of temporary equity into permanent equity.", "label": "Adjustment To Additional Paid In Capital Loss On Conversion Of Temporary Equity Into Permanent Equity", "terseLabel": "Adjustment to additional paid in capital loss on conversion of temporary equity into permanent equity" } } }, "localname": "AdjustmentToAdditionalPaidInCapitalLossOnConversionOfTemporaryEquityIntoPermanentEquity", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "dawn_AgreementAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Agreement [Axis]" } } }, "localname": "AgreementAxis", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "dawn_AgreementDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Agreement [Domain]" } } }, "localname": "AgreementDomain", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_AgreementTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement Type.", "label": "Agreement Type [Axis]" } } }, "localname": "AgreementTypeAxis", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "dawn_AgreementTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement Type.", "label": "Agreement Type [Domain]" } } }, "localname": "AgreementTypeDomain", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_AvailableForSaleMarketableSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Available For Sale Marketable Securities", "label": "Available For Sale Marketable Securities" } } }, "localname": "AvailableForSaleMarketableSecurities", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "dawn_AvailableForSaleMarketableSecuritiesWithMaturities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Available For Sale Marketable Securities with Maturities", "label": "Available For Sale Marketable Securities with Maturities" } } }, "localname": "AvailableForSaleMarketableSecuritiesWithMaturities", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "dawn_AvailableForSaleSecuritie": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Available For Sale Securitie", "label": "Available For Sale Securitie", "terseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritie", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesOfAvailableforsaleMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "dawn_AvailableForSaleSecuritieAmortizedCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Available For Sale Securitie Amortized Cost", "label": "Available For Sale Securitie Amortized Cost", "terseLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleSecuritieAmortizedCost", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesOfAvailableforsaleMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionAccumulatedLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Available For Sale Securitie Continuous Unrealized Loss Position Accumulated Loss", "label": "Available For Sale Securitie Continuous Unrealized Loss Position Accumulated Loss", "terseLabel": "Unrealized losses" } } }, "localname": "AvailableForSaleSecuritieContinuousUnrealizedLossPositionAccumulatedLoss", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Available For Sale Securitie Continuous Unrealized Loss Position Fair Value", "label": "Available For Sale Securitie Continuous Unrealized Loss Position Fair Value", "terseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritieContinuousUnrealizedLossPositionFairValue", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Available For Sale Securitie Continuous Unrealized Loss Position Less Than 12 Months Accumulated Loss", "label": "Available For Sale Securitie Continuous Unrealized Loss Position Less Than 12 Months Accumulated Loss", "terseLabel": "Unrealized Losses Less Than 12 Months, Unrealized losses" } } }, "localname": "AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Available For Sale Securitie Continuous Unrealized Loss Position Less Than Twelve Months Fair Value", "label": "Available For Sale Securitie Continuous Unrealized Loss Position Less Than Twelve Months Fair Value", "terseLabel": "Unrealized Losses Less Than 12 Months, Fair value" } } }, "localname": "AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "dawn_BasisOfIssueAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basis of Issue [Axis]" } } }, "localname": "BasisOfIssueAxis", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "dawn_BasisOfIssueDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basis of Issue [Domain]" } } }, "localname": "BasisOfIssueDomain", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_ClassOfStockSubAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class Of Stock Sub.", "label": "Class of Stock Sub [Axis]" } } }, "localname": "ClassOfStockSubAxis", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "dawn_ClassOfStockSubDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class Of Stock Sub.", "label": "Class of Stock Sub [Domain]" } } }, "localname": "ClassOfStockSubDomain", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_CliffVestingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cliff Vesting.", "label": "Cliff Vesting [Member]", "terseLabel": "Cliff Vesting [Member]" } } }, "localname": "CliffVestingMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_CommonSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common shares", "label": "Common shares [Member]", "verboseLabel": "Common Shares [Member]" } } }, "localname": "CommonSharesMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic" ], "xbrltype": "domainItemType" }, "dawn_CommonSharesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Shares Purchase Agreement.", "label": "Common Shares Purchase Agreement [Member]", "terseLabel": "Common Shares Purchase Agreement [Member]" } } }, "localname": "CommonSharesPurchaseAgreementMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock issued pursuant to follow-on offering, net of issuance costs, Amount", "label": "Common stock issued pursuant to follow-on offering, net of issuance costs, Amount", "terseLabel": "Issuance of common stock pursuant to follow-on offering, net of issuance costs, Amount" } } }, "localname": "CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsAmount", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic" ], "xbrltype": "monetaryItemType" }, "dawn_CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock issued pursuant to follow-on offering, net of issuance costs, Shares", "label": "Common stock issued pursuant to follow-on offering, net of issuance costs, Shares", "terseLabel": "Issuance of common stock pursuant to follow-on offering, net of issuance costs, Shares" } } }, "localname": "CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsShares", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic" ], "xbrltype": "sharesItemType" }, "dawn_CommonStockSharesIssuedAsAResultOfConversionOfTemporaryEquityIntoPermanentEquity": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock shares issued as a result of conversion of temporary equity into permanent equity.", "label": "Common Stock Shares Issued As A Result Of Conversion Of Temporary Equity Into Permanent Equity", "terseLabel": "Common stock shares issued as a result of conversion of temporary equity into permanent equity" } } }, "localname": "CommonStockSharesIssuedAsAResultOfConversionOfTemporaryEquityIntoPermanentEquity", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "dawn_CommonStockSharesIssuedVestingTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock shares issued vesting term.", "label": "Common Stock Shares Issued Vesting Term", "terseLabel": "Common stock shares issued vesting term" } } }, "localname": "CommonStockSharesIssuedVestingTerm", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "dawn_CommonStockSharesUnvested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock shares unvested.", "label": "Common Stock Shares Unvested", "terseLabel": "Common stock shares unvested" } } }, "localname": "CommonStockSharesUnvested", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "dawn_CommonStockToBeIssuedUnderTheEsppTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "common stock to be issued under the ESPP Table text block", "label": "common stock to be issued under the ESPP Table text block", "terseLabel": "Schedule of fair value of our common stock to be issued under the ESPP" } } }, "localname": "CommonStockToBeIssuedUnderTheEsppTableTextBlock", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "dawn_ConditionsForIssueAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Conditions For Issue [Axis]" } } }, "localname": "ConditionsForIssueAxis", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "dawn_ConditionsForIssueDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Conditions For Issue [Domain]" } } }, "localname": "ConditionsForIssueDomain", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_ConversionOfRedeemableNoncontrollingInterestToCommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion of redeemable noncontrolling interest to common stock shares.", "label": "Conversion Of Redeemable Noncontrolling Interest To Common Stock Shares", "terseLabel": "Conversion of redeemable noncontrolling interest to common stock (In shares)" } } }, "localname": "ConversionOfRedeemableNoncontrollingInterestToCommonStockShares", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic" ], "xbrltype": "sharesItemType" }, "dawn_ConversionOfRedeemableNoncontrollingInterestToCommonStockValues": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Conversion of redeemable noncontrolling interest to common stock values.", "label": "Conversion Of Redeemable Noncontrolling Interest To Common Stock Values", "terseLabel": "Conversion of redeemable noncontrolling interest to common stock" } } }, "localname": "ConversionOfRedeemableNoncontrollingInterestToCommonStockValues", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic" ], "xbrltype": "monetaryItemType" }, "dawn_ConversionOfSharesOfOneClassIntoAnother": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion of shares of one class into another.", "label": "Conversion Of Shares Of One Class Into Another", "terseLabel": "Conversion of shares of one class into another" } } }, "localname": "ConversionOfSharesOfOneClassIntoAnother", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "dawn_DayOneHoldingLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Day One Holding LLC.", "label": "Day One Holding LLC [Member]" } } }, "localname": "DayOneHoldingLlcMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_DeferredOfferingCostsNotYetPaid": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred offering costs not yet paid.", "label": "Deferred Offering Costs Not Yet Paid", "terseLabel": "Deferred offering costs not yet paid" } } }, "localname": "DeferredOfferingCostsNotYetPaid", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "dawn_DeferredSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Shares Outstanding.", "label": "Deferred Shares Outstanding", "terseLabel": "Deferred Shares Outstanding" } } }, "localname": "DeferredSharesOutstanding", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "dawn_DeferredSharesParValuePerShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Shares Par Value Per Shares.", "label": "Deferred Shares Par Value Per Shares", "terseLabel": "Deferred Shares Par Value Per Shares" } } }, "localname": "DeferredSharesParValuePerShares", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "dawn_DefinedContributionPlanEmployerMatchingContribution": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Defined Contribution Plan Employer Matching Contribution", "label": "Defined Contribution Plan Employer Matching Contribution", "terseLabel": "Matching Contribution" } } }, "localname": "DefinedContributionPlanEmployerMatchingContribution", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dawn_DepositsAndOtherLongtermAssetsNonCurrent": { "auth_ref": [], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deposits and other long-term assets Non current.", "label": "Deposits and other longterm assets Non current", "terseLabel": "Deposits and other long-term assets" } } }, "localname": "DepositsAndOtherLongtermAssetsNonCurrent", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "dawn_DetailsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Details [Axis]" } } }, "localname": "DetailsAxis", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "dawn_DetailsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Details [Domain]" } } }, "localname": "DetailsDomain", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_DotOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DOT One.", "label": "DOT One [Member]", "terseLabel": "DOT -1 [Member]" } } }, "localname": "DotOneMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_EmergingGrowthCompanyStatusPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Emerging Growth Company Status Policy Text Block", "label": "Emerging Growth Company Status Policy Text Block", "terseLabel": "Emerging growth company status" } } }, "localname": "EmergingGrowthCompanyStatusPolicyTextBlock", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "dawn_EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee Stock Purchase Plan [Member]", "label": "Employee Stock Purchase Plan [Member]" } } }, "localname": "EmployeeStockPurchasePlanMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails" ], "xbrltype": "domainItemType" }, "dawn_ExchangeOfPreferredCommonAndIncentiveSharesInConnectionWithTheConversion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Exchange of preferred, common, and incentive shares in connection with the Conversion.", "label": "Exchange of Preferred, Common, and Incentive Shares in Connection with the Conversion", "terseLabel": "Exchange of 45,331,483 preferred, common, and incentive shares in connection with the Conversion (Note 1)" } } }, "localname": "ExchangeOfPreferredCommonAndIncentiveSharesInConnectionWithTheConversion", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "dawn_ExchangeOfRedeemableConvertibleNoncontrollingInterestToSharesOfCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Exchange of Redeemable Convertible Noncontrolling Interest to Shares of Common Stock.", "label": "Exchange of Redeemable Convertible Noncontrolling Interest to Shares of Common stock", "terseLabel": "Exchange of redeemable convertible noncontrolling interest to 6,470,382 shares of common stock (Note 11)" } } }, "localname": "ExchangeOfRedeemableConvertibleNoncontrollingInterestToSharesOfCommonStock", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "dawn_FirstAnniversaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First Anniversary [Member]", "label": "First Anniversary [Member]", "terseLabel": "First Anniversary" } } }, "localname": "FirstAnniversaryMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_FoundationMedicineIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foundation Medicine, Inc. [Member]", "label": "Foundation Medicine, Inc. [Member]" } } }, "localname": "FoundationMedicineIncMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dawn_FounderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Founder [Member]", "terseLabel": "Founder [Member]" } } }, "localname": "FounderMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_FounderOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Founder One [Member]", "terseLabel": "Founder One [Member]" } } }, "localname": "FounderOneMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_FounderTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Founder two [Member]", "terseLabel": "Founder Two [Member]" } } }, "localname": "FounderTwoMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_GrossProceeds": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross proceeds", "label": "Gross Proceeds", "terseLabel": "Gross proceeds from issuance of common stock" } } }, "localname": "GrossProceeds", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "dawn_GrossProceedsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross Proceeds.", "label": "Gross Proceeds [Member]" } } }, "localname": "GrossProceedsMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_IncentiveSharePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incentive Share Plan.", "label": "Incentive Share Plan [Member]" } } }, "localname": "IncentiveSharePlanMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_IncentiveSharePlanMemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incentive Share Plan Member.", "label": "Incentive Share Plan Member [Member]" } } }, "localname": "IncentiveSharePlanMemberMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail" ], "xbrltype": "domainItemType" }, "dawn_IncentiveSharesAndStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incentive Shares And Stock Options.", "label": "Incentive Shares And Stock Options [Member]", "terseLabel": "Incentive Shares and Stock Options [Member]" } } }, "localname": "IncentiveSharesAndStockOptionsMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_IncentiveSharesCancelledDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incentive shares cancelled during period", "label": "Incentive Shares Cancelled During Period", "terseLabel": "Cancellations of incentive shares" } } }, "localname": "IncentiveSharesCancelledDuringPeriod", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic" ], "xbrltype": "sharesItemType" }, "dawn_IncentiveSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incentive shares.", "label": "Incentive Shares [Member]", "verboseLabel": "Incentive Shares" } } }, "localname": "IncentiveSharesMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheIncentiveSharesActivityDetail", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic" ], "xbrltype": "domainItemType" }, "dawn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in accrued expenses and other current liabilities.", "label": "Increase (Decrease) In Accrued Expenses And Other Current Liabilities", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "dawn_IncreaseDecreaseInOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase Decrease In Operating Lease Liabilities.", "label": "Increase Decrease In Operating Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "dawn_IncrementalSharesReservedForFutureIssuanceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incremental Shares Reserved For Future Issuance.", "label": "Incremental Shares Reserved For Future Issuance [Member]", "terseLabel": "Incremental Shares Reserved for Future Issuance [Member]" } } }, "localname": "IncrementalSharesReservedForFutureIssuanceMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_LeaseCommencementDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Commencement Date1", "label": "Lease Commencement Date1", "terseLabel": "Lease commencement date" } } }, "localname": "LeaseCommencementDate1", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "gYearMonthItemType" }, "dawn_LeaseForCorporateOfficeFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease For Corporate Office Facility [Member]", "terseLabel": "Lease For Corporate Office Facility" } } }, "localname": "LeaseForCorporateOfficeFacilityMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_LesseeOperatingLeaseIncrementalBorrowingRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee operating lease incremental borrowing rate.", "label": "Lessee Operating Lease Incremental Borrowing Rate", "terseLabel": "Lessee operating lease incremental borrowing rate" } } }, "localname": "LesseeOperatingLeaseIncrementalBorrowingRate", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "dawn_MarketableSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Marketable securities [Member]", "label": "Marketable securities [Member]" } } }, "localname": "MarketableSecuritiesMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails" ], "xbrltype": "domainItemType" }, "dawn_MerckLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Merck License Agreement.", "label": "Merck License Agreement [Member]" } } }, "localname": "MerckLicenseAgreementMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/SignificantAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_MilestoneAchievedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone Achieved.", "label": "Milestone Achieved [Member]" } } }, "localname": "MilestoneAchievedMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_MilestoneAchievementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone Achievement.", "label": "Milestone Achievement [Member]" } } }, "localname": "MilestoneAchievementMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_MillenniumPharmaceuticalsInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Millennium Pharmaceuticals, Inc.", "label": "Millennium Pharmaceuticals, Inc. [Member]" } } }, "localname": "MillenniumPharmaceuticalsInc.Member", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_ModifiedStockOptionAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Modified Stock Option Awards [Member]", "label": "Modified Stock Option Awards [Member]", "terseLabel": "Modified Stock Option Awards [Member]" } } }, "localname": "ModifiedStockOptionAwardsMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_NetIncomeLossAvailableToCommonStockholdersBasicNotAffectingCumulativeLosses": { "auth_ref": [], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net income loss available to common stockholders basic not affecting cumulative losses.", "label": "Net Income Loss Available To Common Stockholders Basic Not Affecting Cumulative Losses", "terseLabel": "Net loss attributable to common share members/common stockholders", "totalLabel": "Net loss attributable to common stockholders/members" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicNotAffectingCumulativeLosses", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersStockholdersDetail", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "dawn_NumberOfDirectorsEntitledToBeElectedByTheHoldersOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of directors entitled to be elected by the holders of common stock.", "label": "Number Of Directors Entitled To Be Elected By The Holders Of Common Stock", "terseLabel": "Number of directors entitled to be elected by the holders of common stock" } } }, "localname": "NumberOfDirectorsEntitledToBeElectedByTheHoldersOfCommonStock", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "pureItemType" }, "dawn_NumberOfEmployees": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Employees", "label": "Number of Employees", "terseLabel": "Number of employees" } } }, "localname": "NumberOfEmployees", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "dawn_OperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureLeaseObligationsDetail3": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating lease liabilities", "label": "Operating Lease Liabilities", "totalLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilities", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesSummaryOfFutureLeaseObligationsDetail" ], "xbrltype": "monetaryItemType" }, "dawn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization Consolidation And Presentation Of Financial Statements.", "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "dawn_OrganizationconsolidationandpresentationoffinancialstatementstableTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization Consolidation And Presentation Of Financial Statements Table.", "label": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable [Table]" } } }, "localname": "OrganizationconsolidationandpresentationoffinancialstatementstableTable", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "dawn_ParticipatingThreshold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Participating threshold.", "label": "Participating Threshold", "terseLabel": "Participating threshold" } } }, "localname": "ParticipatingThreshold", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail" ], "xbrltype": "perShareItemType" }, "dawn_PaymentOfAccruedInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment of accrued interest.", "label": "Payment Of Accrued Interest", "terseLabel": "Payment of accrued interest" } } }, "localname": "PaymentOfAccruedInterest", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "dawn_PaymentOfMilestones": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payment of Milestones.", "label": "Payment of Milestones", "terseLabel": "Payable amount upon the completion of trigger events", "verboseLabel": "Payment of Milestones" } } }, "localname": "PaymentOfMilestones", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "http://www.dayonebio.com/20220630/taxonomy/role/SignificantAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "dawn_PaymentsToAcquireProcessResearchAndDevelopmentAssets": { "auth_ref": [], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments To Acquire Process\u00a0Research and Development Assets.", "label": "Payments To Acquire Process Research and Development Assets", "negatedLabel": "Cash paid for acquired\u00a0in-process\u00a0research and development assets" } } }, "localname": "PaymentsToAcquireProcessResearchAndDevelopmentAssets", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "dawn_PerformanceStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance Stock Options Member", "label": "Performance Stock Options [Member]", "terseLabel": "PSOs" } } }, "localname": "PerformanceStockOptionsMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails", "http://www.dayonebio.com/20220630/taxonomy/role/NetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesHaveBeenExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "dawn_PerformanceStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance Stock Units Member", "label": "Performance Stock Units [Member]", "terseLabel": "PSUs" } } }, "localname": "PerformanceStockUnitsMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/NetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesHaveBeenExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "dawn_PrepaidResearchAndDevelopmentExpenses": { "auth_ref": [], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPrepaidAndOtherCurrentAssetsDetail": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid Research and Development Expenses.", "label": "Prepaid research and development expenses", "verboseLabel": "Prepaid research and development expenses" } } }, "localname": "PrepaidResearchAndDevelopmentExpenses", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPrepaidAndOtherCurrentAssetsDetail" ], "xbrltype": "monetaryItemType" }, "dawn_RedeemableNonControllingInterestTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of redeemable non-controlling interest.", "label": "Redeemable Non Controlling Interest [Text Block]", "terseLabel": "Redeemable NonControlling Interest" } } }, "localname": "RedeemableNonControllingInterestTextBlock", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableNoncontrollingInterest" ], "xbrltype": "textBlockItemType" }, "dawn_RedeemableNoncontrollingInterestMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redeemable Noncontrolling Interest [Member]" } } }, "localname": "RedeemableNoncontrollingInterestMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic" ], "xbrltype": "domainItemType" }, "dawn_ResearchAndDevelopmentAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Research And Development Agreements [Member]", "terseLabel": "Research And Development Agreements" } } }, "localname": "ResearchAndDevelopmentAgreementsMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_RightOfUseAssetCapitalization": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Right of Use Asset Capitalization.", "label": "Right of Use Asset Capitalization", "terseLabel": "Right of use asset capitalization" } } }, "localname": "RightOfUseAssetCapitalization", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "dawn_RoyaltyFeePayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Royalty fee payable.", "label": "Royalty Fee Payable", "terseLabel": "Royalty fee payable" } } }, "localname": "RoyaltyFeePayable", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "dawn_SalesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales agreement member", "label": "Sales Agreement [Member]", "terseLabel": "Sales Agreement with Piper Sandler and Jones Services LLC [Member]" } } }, "localname": "SalesAgreementMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_ScheduleOfAvailableForSaleMarketableSecuritiesWithGrossUnrealizedLossesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of available-for-sale marketable securities with gross unrealized losses table text block", "label": "Schedule of available-for-sale marketable securities with gross unrealized losses table text block", "terseLabel": "Schedule of available-for-sale marketable securities with gross unrealized losses" } } }, "localname": "ScheduleOfAvailableForSaleMarketableSecuritiesWithGrossUnrealizedLossesTableTextBlock", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementTables" ], "xbrltype": "textBlockItemType" }, "dawn_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Common Stock Shares Reserved For Future Issuance Table Text Block", "label": "Schedule Of Common Stock Shares Reserved For Future Issuance [Table Text Block]", "terseLabel": "Schedule of Common Stock Shares Reserved for Future Issuance" } } }, "localname": "ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockTables" ], "xbrltype": "textBlockItemType" }, "dawn_ScheduleOfMaturitiesOfOurAvailableForSaleMarketableSecuritiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of maturities of our available-for-sale marketable securities table text block", "label": "Schedule of maturities of our available-for-sale marketable securities table text block" } } }, "localname": "ScheduleOfMaturitiesOfOurAvailableForSaleMarketableSecuritiesTableTextBlock", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementTables" ], "xbrltype": "textBlockItemType" }, "dawn_ScheduleOfPerformanceStockOptionsAssumptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Performance Stock Options Assumptions table text block", "label": "Schedule of Performance Stock Options Assumptions [Table Text Block]", "terseLabel": "Summary of The Black-Scholes Option Pricing Model to Estimate The Fair Value of Performance Stock Option Granted" } } }, "localname": "ScheduleOfPerformanceStockOptionsAssumptionsTableTextBlock", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "dawn_ScheduleOfPrepaidAndOtherCurrentAssetstableTextBlockTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Prepaid And Other Current Assets.", "label": "Schedule Of Prepaid And Other Current Assets [Table Text Block]", "verboseLabel": "Schedule of Prepaid and Other Current Assets" } } }, "localname": "ScheduleOfPrepaidAndOtherCurrentAssetstableTextBlockTableTextBlock", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsTables" ], "xbrltype": "textBlockItemType" }, "dawn_ScheduleOfStockOptionsAssumptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Stock Options Assumptions.", "label": "Schedule of Stock Options Assumptions [Table Text Block]", "verboseLabel": "Summary of The Black-Scholes Option Pricing Model to Estimate The Fair Value of Stock Option Granted" } } }, "localname": "ScheduleOfStockOptionsAssumptionsTableTextBlock", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "dawn_SeriesARedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A Redeemable Convertible Preferred Stock.", "label": "Series A Redeemable Convertible Preferred Stock [Member]" } } }, "localname": "SeriesARedeemableConvertiblePreferredStockMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesSummaryOfSeriesARedeemableConvertiblePreferredSharesDetail", "http://www.dayonebio.com/20220630/taxonomy/role/SignificantAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_SeriesBRedeemableConvertiblePreferredSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B Redeemable Convertible Preferred Shares.", "label": "Series B redeemable convertible preferred shares [Member]" } } }, "localname": "SeriesBRedeemableConvertiblePreferredSharesMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic1", "http://www.dayonebio.com/20220630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_SeriesBRedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B Redeemable Convertible Preferred Stock.", "label": "Series B Redeemable Convertible Preferred Stock [Member]" } } }, "localname": "SeriesBRedeemableConvertiblePreferredStockMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_SeriesBRedeemableConvertiblePreferredStockSharesIssuedDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B redeemable convertible preferred stock shares issued during period", "label": "Series B Redeemable Convertible Preferred Stock Shares Issued During Period", "terseLabel": "Issuance of Series B redeemable convertible preferred shares for cash, net of issuance costs, shares" } } }, "localname": "SeriesBRedeemableConvertiblePreferredStockSharesIssuedDuringPeriod", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic" ], "xbrltype": "sharesItemType" }, "dawn_SeriesBRedeemableConvertiblePreferredStockValueIssuedDuringPeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Series B redeemable convertible preferred stock value Issued during period", "label": "Series B Redeemable Convertible Preferred Stock Value Issued During Period", "terseLabel": "Issuance of Series B redeemable convertible preferred shares for cash, net of issuance costs" } } }, "localname": "SeriesBRedeemableConvertiblePreferredStockValueIssuedDuringPeriod", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic" ], "xbrltype": "monetaryItemType" }, "dawn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStockWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options converted to unvested common stock weighted average grant date fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Converted To Unvested Common Stock Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value, Converted to unvested common stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStockWeightedAverageGrantDateFairValue", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheIncentiveSharesActivityDetail" ], "xbrltype": "perShareItemType" }, "dawn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average grant date fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheIncentiveSharesActivityDetail" ], "xbrltype": "perShareItemType" }, "dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation by share based payment arrangement equity instruments other than options converted to unvested common stock.", "label": "Share Based Compensation By Share Based Payment Arrangement Equity Instruments Other Than Options Converted To Unvested Common Stock", "terseLabel": "Number of Shares, Converted to unvested common stock" } } }, "localname": "ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStock", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheIncentiveSharesActivityDetail" ], "xbrltype": "sharesItemType" }, "dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation by share based payment arrangement equity instruments other than options outstanding.", "label": "Share Based Compensation By Share Based Payment Arrangement Equity Instruments Other Than Options Outstanding", "periodEndLabel": "Number of Shares, Unvasted Common Stock, Ending balance", "periodStartLabel": "Number of Shares, Unvasted Common Stock, Beginning balance" } } }, "localname": "ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheIncentiveSharesActivityDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheUnvestedCommonStockDetail" ], "xbrltype": "sharesItemType" }, "dawn_ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveShareIntoRestrictedStockWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation by share based payment award conversion of incentive share into restricted stock weighted average grant date fair value.", "label": "Share Based Compensation By Share Based Payment Award Conversion Of Incentive Share Into Restricted Stock Weighted Average Grant Date Fair Value", "terseLabel": "Conversion of incentive shares" } } }, "localname": "ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveShareIntoRestrictedStockWeightedAverageGrantDateFairValue", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheUnvestedCommonStockDetail" ], "xbrltype": "perShareItemType" }, "dawn_ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveSharesIntoRestrictedStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation by share based payment award conversion of incentive shares into restricted stock.", "label": "Share Based Compensation By Share Based Payment Award Conversion Of Incentive Shares Into Restricted Stock", "terseLabel": "Conversion of incentive shares" } } }, "localname": "ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveSharesIntoRestrictedStock", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheUnvestedCommonStockDetail" ], "xbrltype": "sharesItemType" }, "dawn_ShareBasedCompensationBySharePaymentArrangementIntrinsicValueOfNonVestedOutstandingOptions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share based compensation by share payment arrangement intrinsic value of non vested outstanding options.", "label": "Share Based Compensation By Share Payment Arrangement Intrinsic Value Of Non Vested Outstanding Options", "terseLabel": "Share based compensation by share based arrangement intrinsic value of non vested outstanding options" } } }, "localname": "ShareBasedCompensationBySharePaymentArrangementIntrinsicValueOfNonVestedOutstandingOptions", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "dawn_ShareBasedCompensationBySharePaymentArrangementWeightedAverageRemainingContractualLifeOfNonVestedOutstandingOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation by share payment arrangement weighted average remaining contractual life of non vested outstanding options.", "label": "Share Based Compensation By Share Payment Arrangement Weighted Average Remaining Contractual Life Of Non Vested Outstanding Options", "terseLabel": "Share based compensation by share based payment arrangement weighted average remaining contractual life of non vested outstanding options" } } }, "localname": "ShareBasedCompensationBySharePaymentArrangementWeightedAverageRemainingContractualLifeOfNonVestedOutstandingOptions", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "dawn_SharesCommittedUnderESPPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares Committed Under E S P P.", "label": "Shares Committed Under E S P P [Member]", "terseLabel": "Shares committed under ESPP" } } }, "localname": "SharesCommittedUnderESPPMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/NetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesHaveBeenExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "dawn_StockIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Stock issuance costs.", "label": "Stock Issuance Costs", "terseLabel": "Stock issuance costs" } } }, "localname": "StockIssuanceCosts", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic1" ], "xbrltype": "monetaryItemType" }, "dawn_TakedaAssetAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Takeda Asset Agreement.", "label": "Takeda Asset Agreement [Member]" } } }, "localname": "TakedaAssetAgreementMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/SignificantAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_TakedaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Takeda.", "label": "Takeda [Member]" } } }, "localname": "TakedaMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_TemporaryEquityIssuePricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity issue price per share.", "label": "Temporary Equity Issue Price Per Share", "terseLabel": "Temporary equity issue price per share" } } }, "localname": "TemporaryEquityIssuePricePerShare", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "dawn_TemporaryEquityRelatedTrancheLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary Equity Related Tranche Liability.", "label": "Temporary Equity Related Tranche Liability [Member]" } } }, "localname": "TemporaryEquityRelatedTrancheLiabilityMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_TemporaryEquitySharesConvertedIntoPermanentEquity": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity shares converted into permanent equity.", "label": "Temporary Equity Shares Converted Into Permanent Equity", "terseLabel": "Temporary equity shares converted into permanent equity" } } }, "localname": "TemporaryEquitySharesConvertedIntoPermanentEquity", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "dawn_TemporaryEquityStockIssuedDuringThePeriodSharesNewIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity stock issued during the period shares new issues.", "label": "Temporary Equity Stock Issued During The Period Shares New Issues", "terseLabel": "Temporary equity stock issued during the period shares new issues" } } }, "localname": "TemporaryEquityStockIssuedDuringThePeriodSharesNewIssues", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "dawn_TemporaryEquityTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary Equity [Text Block].", "label": "Temporary Equity [Text Block]", "terseLabel": "Redeemable Convertible Preferred Shares" } } }, "localname": "TemporaryEquityTextBlock", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredShares" ], "xbrltype": "textBlockItemType" }, "dawn_TheMillenniumStockExchangeAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Millennium Stock Exchange Agreement.", "label": "The Millennium Stock Exchange Agreement [Member]" } } }, "localname": "TheMillenniumStockExchangeAgreementMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_TovorafenibMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "tovorafenib [Member]", "label": "tovorafenib [Member]", "terseLabel": "Tovorafenib [Member]" } } }, "localname": "TovorafenibMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dawn_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 employee stock purchase plan.", "label": "Two Thousand And Twenty One Employee Stock Purchase Plan [Member]", "terseLabel": "2021 Employee Stock Purchase Plan [Member]" } } }, "localname": "TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand and twenty one equity incentive plan.", "label": "Two Thousand And Twenty One Equity Incentive Plan [Member]", "terseLabel": "2021 Equity Incentive Plan [Member]" } } }, "localname": "TwoThousandAndTwentyOneEquityIncentivePlanMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityUnderThe2021PlanDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail" ], "xbrltype": "domainItemType" }, "dawn_TwoThousandAndTwentyOneStockIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand and twenty one stock incentive plan.", "label": "2021 Stock Incentive Plan [Member]", "terseLabel": "Two Thousand And Twenty One Stock Incentive Plan [Member]" } } }, "localname": "TwoThousandAndTwentyOneStockIncentivePlanMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitsActivityDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheUnvestedCommonStockDetail" ], "xbrltype": "domainItemType" }, "dawn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Twenty One Employee Stock Purchase Plan [Member]", "label": "Two Thousand Twenty One Employee Stock Purchase Plan [Member]", "terseLabel": "2021 Employee Stock Purchase Plan [Member]" } } }, "localname": "TwoThousandTwentyOneEmployeeStockPurchasePlanMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationFairValueOfOurCommonStockToBeIssuedUnderTheEsppDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail" ], "xbrltype": "domainItemType" }, "dawn_UnamortizedStockBasedCompensationForStockOptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unamortized stock-based compensation for stock options", "label": "Unamortized stock-based compensation for stock options", "terseLabel": "Unamortized stock-based compensation for stock options" } } }, "localname": "UnamortizedStockBasedCompensationForStockOptions", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "dawn_UnvestedCommonSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unvested common shares.", "label": "Unvested Common Shares [Member]", "terseLabel": "Unvested common shares" } } }, "localname": "UnvestedCommonSharesMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/NetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesHaveBeenExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "dawn_UnvestedCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unvested Common Stock.", "label": "Unvested Common Stock [Member]" } } }, "localname": "UnvestedCommonStockMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_UnvestedIncentiveSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unvested Incentive Shares.", "label": "Unvested Incentive Shares [Member]", "terseLabel": "Unvested Incentive Shares [Member]" } } }, "localname": "UnvestedIncentiveSharesMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_UnvestedPsosAndPsusMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unvested PSOs and PSUs [Member]", "label": "Unvested PSOs and PSUs [Member]" } } }, "localname": "UnvestedPsosAndPsusMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_UnvestedRestrictedStockAndStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unvested Restricted Stock And Stock Options.", "label": "Unvested Restricted Stock And Stock Options [Member]", "terseLabel": "Unvested Restricted Stock and Stock Options [Member]" } } }, "localname": "UnvestedRestrictedStockAndStockOptionsMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_UpfrontOfCashPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Upfront of Cash Payment.", "label": "upfront of cash payment", "verboseLabel": "Upfront of cash payment" } } }, "localname": "UpfrontOfCashPayment", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/SignificantAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "dawn_UpfrontPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Upfront payment.", "label": "Upfront Payment", "verboseLabel": "Upfront payment" } } }, "localname": "UpfrontPayment", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/SignificantAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "dawn_ViractaLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Viracta License Agreement [Member]", "terseLabel": "Viracta License Agreement" } } }, "localname": "ViractaLicenseAgreementMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/SignificantAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dawn_WithinOneYearMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Within One Year [Member]", "label": "Within One Year [Member]", "terseLabel": "Within 1 year [Member]" } } }, "localname": "WithinOneYearMember", "nsuri": "http://www.dayonebio.com/20220630", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesOfAvailableforsaleMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "verboseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "verboseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "verboseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "verboseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "verboseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "verboseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "verboseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "verboseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "verboseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "verboseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "verboseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "verboseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "verboseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "verboseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "verboseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "verboseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "verboseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "verboseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "verboseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "verboseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "verboseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r491" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "verboseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "verboseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "verboseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "verboseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r490" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "verboseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "verboseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "verboseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "verboseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "verboseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "verboseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "verboseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r480" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "verboseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "verboseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_CentralAmericaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Central America [Member]", "terseLabel": "Central America" } } }, "localname": "CentralAmericaMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r178", "r179", "r180", "r181", "r196", "r214", "r254", "r255", "r386", "r387", "r388", "r389", "r390", "r391", "r411", "r453", "r455", "r475", "r476" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail", "http://www.dayonebio.com/20220630/taxonomy/role/SignificantAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r178", "r179", "r180", "r181", "r196", "r214", "r254", "r255", "r386", "r387", "r388", "r389", "r390", "r391", "r411", "r453", "r455", "r475", "r476" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r171", "r178", "r179", "r180", "r181", "r196", "r214", "r242", "r254", "r255", "r285", "r286", "r287", "r386", "r387", "r388", "r389", "r390", "r391", "r411", "r453", "r455", "r475", "r476" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail", "http://www.dayonebio.com/20220630/taxonomy/role/SignificantAgreementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r171", "r178", "r179", "r180", "r181", "r196", "r214", "r242", "r254", "r255", "r285", "r286", "r287", "r386", "r387", "r388", "r389", "r390", "r391", "r411", "r453", "r455", "r475", "r476" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail", "http://www.dayonebio.com/20220630/taxonomy/role/SignificantAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r133", "r134", "r240", "r241", "r454", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r133", "r134", "r240", "r241", "r454", "r464", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r26" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "totalLabel": "Total accrued expenses and other current liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r25", "r376" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.", "label": "Accrued Liabilities and Other Liabilities", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Accrued Liabilities and Other Liabilities, Total" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedMarketingCostsCurrent": { "auth_ref": [], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Marketing Costs, Current", "verboseLabel": "Accrued issuance costs" } } }, "localname": "AccruedMarketingCostsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedPayrollTaxesCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Payroll Taxes, Current", "verboseLabel": "Accrued payroll related expenses" } } }, "localname": "AccruedPayrollTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "verboseLabel": "Accrued professional service expenses" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r9", "r168" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentDetail": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total", "verboseLabel": "Less: accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r18", "r41", "r42", "r43", "r443", "r460", "r461" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r40", "r43", "r49", "r50", "r51", "r82", "r83", "r84", "r318", "r370", "r456", "r457" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r16", "r376" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "periodEndLabel": "Additional Paid in Capital, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Beginning Balance", "terseLabel": "Additional\u00a0paid-in-capital", "totalLabel": "Additional Paid in Capital, Total" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r82", "r83", "r84", "r297", "r298", "r299", "r335" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "verboseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, ESPP, Increase for Cost Recognition", "terseLabel": "ESPP awards" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r257", "r301", "r302" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation expenses", "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r290" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Allocated share based compensation expense", "verboseLabel": "Share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfSharestockbasedCompensationExpenseRecordedInTheAccompanyingCondensedConsolidatedStatementsOfOperatio", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Stock options" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/NetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesHaveBeenExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/NetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesHaveBeenExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/NetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesHaveBeenExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/NetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesHaveBeenExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfLand": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land held.", "label": "Area of Land", "terseLabel": "Sublease agreement area" } } }, "localname": "AreaOfLand", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "http://www.dayonebio.com/20220630/taxonomy/role/SignificantAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r11", "r79", "r125", "r127", "r131", "r151", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r313", "r319", "r348", "r374", "r376", "r426", "r442" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r137", "r158" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "terseLabel": "Debt securities, available-for-sale, amortized cost", "totalLabel": "Debt Securities, Available-for-Sale, Amortized Cost, Total" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain": { "auth_ref": [ "r139" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Unrealized Gain", "terseLabel": "Debt securities, available-for-sale, unrealized Gain" } } }, "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedGain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": { "auth_ref": [ "r140" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Unrealized Loss", "terseLabel": "Debt securities, available-for-sale, unrealized loss" } } }, "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.", "label": "Available-for-Sale Securities", "terseLabel": "Fair value" } } }, "localname": "AvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesOfAvailableforsaleMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAmortizedCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.", "label": "Available-for-Sale Securities, Amortized Cost Basis", "terseLabel": "Amortized cost" } } }, "localname": "AvailableForSaleSecuritiesAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesOfAvailableforsaleMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investments in debt and equity securities classified as available-for-sale that have been in a continuous loss position for twelve months or longer.", "label": "Available-for-Sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "terseLabel": "Unrealized Losses 12 Months or Greater, Unrealized losses" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss": { "auth_ref": [ "r146" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investments in debt and equity securities classified as available-for-sale in a continuous loss position.", "label": "Available-for-Sale Securities, Continuous Unrealized Loss Position, Accumulated Loss", "terseLabel": "Unrealized losses" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the aggregate fair value of investments in debt and equity securities in an unrealized loss position which are categorized neither as held-to-maturity nor trading securities.", "label": "Available-for-Sale Securities, Continuous Unrealized Loss Position, Fair Value", "terseLabel": "Fair value" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investments in debt and equity securities classified as available-for-sale that have been in a continuous loss position for less than twelve months.", "label": "Available-for-Sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "terseLabel": "Unrealized Losses Less Than 12 Months, Unrealized losses" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position for less than twelve months.", "label": "Available-for-Sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Fair Value", "terseLabel": "Unrealized Losses Less Than 12 Months, Fair value" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position for twelve months or longer.", "label": "Available-for-Sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Fair Value", "terseLabel": "Unrealized Losses 12 Months or Greater, Fair value" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": { "auth_ref": [ "r141", "r143", "r439" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesOfAvailableforsaleMarketableSecuritiesDetails2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.", "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value", "totalLabel": "Fair Value, Total" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesOfAvailableforsaleMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": { "auth_ref": [ "r141", "r143", "r437" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesOfAvailableforsaleMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.", "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost", "totalLabel": "Amortized Cost, Total" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesOfAvailableforsaleMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "auth_ref": [ "r142" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesOfAvailableforsaleMarketableSecuritiesDetails": { "order": 0.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Amortized cost, Mature in one year or less" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesOfAvailableforsaleMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r141", "r142", "r438" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesOfAvailableforsaleMarketableSecuritiesDetails2": { "order": 0.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Fair Value, Mature in one year or less" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesOfAvailableforsaleMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r136", "r138", "r158", "r428" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Debt securities, available-for-sale, estimated fair value", "totalLabel": "Debt Securities, Available-for-Sale, Total" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r284", "r285", "r286", "r287", "r288" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitsActivityDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheIncentiveSharesActivityDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheUnvestedCommonStockDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]" } } }, "localname": "BalanceSheetRelatedDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "verboseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r7", "r376", "r462", "r463" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "periodEndLabel": "Cash, Ending Balance", "periodStartLabel": "Cash, Beginning Balance", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r7", "r70" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesOfAvailableforsaleMarketableSecuritiesDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementSummaryOfCompanysFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents, fair value disclosure", "verboseLabel": "Money market funds, included in cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementSummaryOfCompanysFinancialInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Cash and Cash Equivalents [Line Items]" } } }, "localname": "CashAndCashEquivalentsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesOfAvailableforsaleMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "verboseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r65", "r70", "r75" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period", "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r65", "r349" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r7" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "totalLabel": "Cash Equivalents, at Carrying Value, Total", "verboseLabel": "Cash equivalents, at carrying value" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]", "terseLabel": "Cash equivalents [Member]" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r12", "r14", "r15", "r77", "r79", "r98", "r99", "r100", "r103", "r105", "r113", "r114", "r115", "r151", "r185", "r189", "r190", "r191", "r194", "r195", "r212", "r213", "r217", "r221", "r229", "r348", "r483" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "verboseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesSummaryOfSeriesARedeemableConvertiblePreferredSharesDetail", "http://www.dayonebio.com/20220630/taxonomy/role/SignificantAgreementsAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic", "http://www.dayonebio.com/20220630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r308", "r309", "r311" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Significant Agreements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/SignificantAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/SignificantAgreementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r30", "r429", "r447" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 6)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r173", "r174", "r175", "r182", "r465" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.", "label": "Common Class B [Member]" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r31" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common stock shares reserved for future issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r82", "r83", "r335" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "verboseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails", "http://www.dayonebio.com/20220630/taxonomy/role/SignificantAgreementsAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic1" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common Stock, Par or Stated Value Per Share", "verboseLabel": "Common stock par or stated value per share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common Stock, Shares Authorized", "verboseLabel": "Common stock shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common Stock, Shares Issued", "totalLabel": "Common Stock, Shares, Issued, Total" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r15", "r229" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "terseLabel": "Common Stock, Shares Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r15", "r376" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "terseLabel": "Common stock, $0.0001 par value; 500,000,000 shares authorized as of June 30, 2022 and December 31, 2021; 73,461,100 and 61,952,292 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively", "totalLabel": "Common Stock, Value, Issued, Total" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r45", "r47", "r48", "r53", "r432", "r450" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r118", "r441" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of credit risk and other risks and uncertainties" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r72", "r73", "r74" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Converted", "verboseLabel": "Conversion of stock, shares converted" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r72", "r73", "r74" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Issued", "verboseLabel": "Number of shares issued upon conversion" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r13", "r14", "r224", "r230", "r233" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "verboseLabel": "Convertible preferred stock, shares issued upon conversion" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r72", "r74" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued", "terseLabel": "Temporary equity shares issued upon conversion of notes payable" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [ "r146", "r160" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of shares authorized for issuance under the deferred compensation arrangement as of the balance sheet date.", "label": "Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance", "terseLabel": "Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance" } } }, "localname": "DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued pursuant to the terms of a deferred compensation arrangement.", "label": "Deferred Compensation Arrangement with Individual, Shares Issued", "terseLabel": "Deferred Compensation Arrangement with Individual, Shares Issued" } } }, "localname": "DeferredCompensationArrangementWithIndividualSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_DeferredFinanceCostsOwnshareLendingArrangementIssuanceCostsNet": { "auth_ref": [ "r200" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of issuance costs recognized in a share-lending arrangement entered into by the entity, in contemplation of a convertible debt offering or other financing, after deduction of accumulated amortization or the effects of subsequent adjustments.", "label": "Deferred Finance Costs, Own-share Lending Arrangement, Issuance Costs, Net", "totalLabel": "Deferred Finance Costs, Own-share Lending Arrangement, Issuance Costs, Net, Total", "verboseLabel": "Deferred finance costs, own-share lending arrangement, issuance costs, net" } } }, "localname": "DeferredFinanceCostsOwnshareLendingArrangementIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanTextBlock": { "auth_ref": [ "r252", "r253" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for defined contribution plan.", "label": "Defined Contribution Plan [Text Block]", "terseLabel": "Defined Contribution Plan" } } }, "localname": "DefinedContributionPlanTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDefinedContributionPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r68", "r124" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation expense", "totalLabel": "Depreciation, Depletion and Amortization, Total" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r34", "r35", "r36", "r326", "r393" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "terseLabel": "Derivative liability at fair value", "totalLabel": "Derivative Liability, Fair Value, Gross Liability, Total" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r325" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Unrealized gain loss due to change in fair value of derivatives", "totalLabel": "Derivative, Gain (Loss) on Derivative, Net, Total" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r35", "r324", "r327", "r328", "r329" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r260", "r261", "r291", "r292", "r295", "r304" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Equity-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r259", "r296" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]", "terseLabel": "Summary of Stock Option Activity Under The 2021 Plan" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r54", "r87", "r88", "r89", "r90", "r91", "r95", "r98", "r103", "r104", "r105", "r109", "r110", "r336", "r337", "r433", "r451" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Earnings Per Share, Basic", "totalLabel": "Earnings Per Share, Basic, Total", "verboseLabel": "Net loss per share, Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersStockholdersDetail", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r54", "r87", "r88", "r89", "r90", "r91", "r98", "r103", "r104", "r105", "r109", "r110", "r336", "r337", "r433", "r451" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Earnings Per Share, Diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "verboseLabel": "Net loss per share, Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersStockholdersDetail", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r106", "r107", "r108", "r111" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/NetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfSharestockbasedCompensationExpenseRecordedInTheAccompanyingCondensedConsolidatedStatementsOfOperatio" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r294" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Share based compensation by share based payment arrangement unrecognized compensation", "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Share based compensation by share based payment arrangement unrecognized compensation remaining period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Stock options", "verboseLabel": "Share-based Payment Arrangement, Option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail", "http://www.dayonebio.com/20220630/taxonomy/role/NetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesHaveBeenExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r49", "r50", "r51", "r82", "r83", "r84", "r86", "r92", "r94", "r112", "r152", "r229", "r237", "r297", "r298", "r299", "r306", "r307", "r335", "r350", "r351", "r352", "r353", "r354", "r355", "r370", "r456", "r457", "r458" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails", "http://www.dayonebio.com/20220630/taxonomy/role/SignificantAgreementsAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic1" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementSummaryOfCompanysFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r338", "r339", "r344" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesOfAvailableforsaleMarketableSecuritiesDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementSummaryOfCompanysFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementSummaryOfCompanysFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r338", "r344" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementSummaryOfCompanysFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r197", "r201", "r202", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r251", "r339", "r383", "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementSummaryOfCompanysFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r338", "r339", "r340", "r341", "r345" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementSummaryOfCompanysFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Recurring Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r197", "r243", "r244", "r249", "r251", "r339", "r383" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementSummaryOfCompanysFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r197", "r201", "r202", "r243", "r244", "r249", "r251", "r339", "r384" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementSummaryOfCompanysFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r197", "r201", "r202", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r251", "r339", "r385" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementSummaryOfCompanysFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r338", "r339" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of liabilities measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.", "label": "Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block]", "terseLabel": "Schedule of cash equivalents, marketable securities, and unrealized gains and losses" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementSummaryOfCompanysFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net", "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net, Total", "verboseLabel": "Fair value, measurement recurring basis, asset, transfers, net" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r197", "r201", "r202", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r251", "r383", "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementSummaryOfCompanysFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r343", "r345" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementSummaryOfCompanysFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r346", "r347" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r144", "r145", "r147", "r148", "r149", "r153", "r154", "r155", "r156", "r157", "r159", "r161", "r162", "r163", "r199", "r227", "r332", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r483", "r484", "r485", "r486", "r487", "r488", "r489" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and Fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r57" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited2": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative", "totalLabel": "General and Administrative Expense, Total" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfSharestockbasedCompensationExpenseRecordedInTheAccompanyingCondensedConsolidatedStatementsOfOperatio" ], "xbrltype": "domainItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r170", "r172" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfSharestockbasedCompensationExpenseRecordedInTheAccompanyingCondensedConsolidatedStatementsOfOperatio", "http://www.dayonebio.com/20220630/taxonomy/role/SignificantAgreementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfSharestockbasedCompensationExpenseRecordedInTheAccompanyingCondensedConsolidatedStatementsOfOperatio", "http://www.dayonebio.com/20220630/taxonomy/role/SignificantAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r67" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "totalLabel": "Increase (Decrease) in Accounts Payable, Total" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDepositOtherAssets": { "auth_ref": [ "r67" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.", "label": "Increase (Decrease) in Deposit Assets", "negatedLabel": "Deposits and other long-term assets", "totalLabel": "Increase (Decrease) in Deposit Assets, Total" } } }, "localname": "IncreaseDecreaseInDepositOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r67" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndemnificationGuaranteeMember": { "auth_ref": [ "r183", "r184" ], "lang": { "en-us": { "role": { "documentation": "An agreement (contract) that contingently requires the guarantor to make payments to the guaranteed party in compensation for that party's or parties' loss or injury attributable to specified events or actions, such as a patent infringement action against an entity that relied on certain representations as to ownership rights made by a software vendor.", "label": "Indemnification Agreement [Member]", "terseLabel": "Indemnification Agreement" } } }, "localname": "IndemnificationGuaranteeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r434" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited2": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "terseLabel": "Interest income (expense), net", "totalLabel": "Interest Income (Expense), Net, Total" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r150", "r452" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Operating Leases, Rent Expense", "terseLabel": "Total payments for base rent", "totalLabel": "Operating Leases, Rent Expense, Total" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseContractualTermAxis": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Information by contractual term of lease arrangement.", "label": "Lease Contractual Term [Axis]" } } }, "localname": "LeaseContractualTermAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseContractualTermDomain": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement.", "label": "Lease Contractual Term [Domain]" } } }, "localname": "LeaseContractualTermDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseDepositLiability": { "auth_ref": [ "r369" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability for lease payments received, including variable lease payments, when collectability is not probable at commencement date for sales-type lease.", "label": "Lease Deposit Liability", "terseLabel": "Security deposit" } } }, "localname": "LeaseDepositLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r167" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeFinanceLeaseTermOfContract1": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Finance Lease, Term of Contract", "terseLabel": "Initial lease term" } } }, "localname": "LesseeFinanceLeaseTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Summary of Future Lease Obligations" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r367" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesSummaryOfFutureLeaseObligationsDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureLeaseObligationsDetail2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total future minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesSummaryOfFutureLeaseObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r367" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesSummaryOfFutureLeaseObligationsDetail": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesSummaryOfFutureLeaseObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r367" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesSummaryOfFutureLeaseObligationsDetail": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesSummaryOfFutureLeaseObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r367" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesSummaryOfFutureLeaseObligationsDetail": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Remaining in 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesSummaryOfFutureLeaseObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r367" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureLeaseObligationsDetail2": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Imputed interest", "terseLabel": "Less: Imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesSummaryOfFutureLeaseObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Lessee operating lease renewal lease term" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Operating lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r27", "r79", "r128", "r151", "r185", "r186", "r187", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r314", "r319", "r320", "r348", "r374", "r375" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r21", "r79", "r151", "r348", "r376", "r427", "r445" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r5", "r29", "r79", "r151", "r185", "r186", "r187", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r314", "r319", "r320", "r348", "r374", "r375", "r376" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r176", "r177" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "periodEndLabel": "Loss Contingency Accrual, Ending Balance", "periodStartLabel": "Loss Contingency Accrual, Beginning Balance", "terseLabel": "Termination and cancellation charges payable", "verboseLabel": "Litigation amount awarded from other party" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecurities": { "auth_ref": [ "r430" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security.", "label": "Marketable Securities", "terseLabel": "Short-term investments", "totalLabel": "Marketable Securities, Total" } } }, "localname": "MarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementSummaryOfCompanysFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r65" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r65" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r65", "r66", "r69" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r44", "r46", "r51", "r52", "r69", "r79", "r85", "r87", "r88", "r89", "r90", "r93", "r94", "r101", "r125", "r126", "r129", "r130", "r132", "r151", "r185", "r186", "r187", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r337", "r348", "r431", "r449" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net Income (Loss) Attributable to Parent, Total", "verboseLabel": "Net loss attributable to Day One Biopharmaceuticals Holding Company, LLC members" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r44", "r46", "r51", "r93", "r94", "r316", "r321" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedLabel": "Net loss attributable to redeemable convertible noncontrolling interests", "totalLabel": "Net Income (Loss) Attributable to Noncontrolling Interest, Total" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersStockholdersDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest": { "auth_ref": [ "r56" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited2": { "order": 1.0, "parentTag": "dawn_NetIncomeLossAvailableToCommonStockholdersBasicNotAffectingCumulativeLosses", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.", "label": "Net Income (Loss) Attributable to Redeemable Noncontrolling Interest", "negatedLabel": "Net loss attributable to redeemable convertible noncontrolling interests", "terseLabel": "Net loss attributable to redeemable convertible noncontrolling interests", "totalLabel": "Net Income (Loss) Attributable to Redeemable Noncontrolling Interest, Total" } } }, "localname": "NetIncomeLossAttributableToRedeemableNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableNoncontrollingInterestAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r87", "r88", "r89", "r90", "r95", "r96", "r102", "r105", "r125", "r126", "r129", "r130", "r132" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net Income (Loss) Available to Common Stockholders, Basic, Total", "verboseLabel": "Net loss attributable to common stockholders/members'" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited2": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r125", "r126", "r129", "r130", "r132" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited2": { "order": 0.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r358" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureLeaseObligationsDetail2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureLeaseObligationsDetail3": { "order": 0.0, "parentTag": "dawn_OperatingLeaseLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Present value of operating lease liabilities", "totalLabel": "Present value of operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesSummaryOfFutureLeaseObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r358" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureLeaseObligationsDetail3": { "order": 1.0, "parentTag": "dawn_OperatingLeaseLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liabilities", "verboseLabel": "Less: current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesSummaryOfFutureLeaseObligationsDetail", "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r358" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, long-term", "verboseLabel": "Long-term portion of lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r359", "r363" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating lease payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r357" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease\u00a0right-of-use\u00a0asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r68" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Operating Lease, Right-of-Use Asset, Amortization Expense", "negatedLabel": "Amortization of operating right-of-use assets", "terseLabel": "Amortization of operating right-of-use assets", "verboseLabel": "Amortization of operating\u00a0right-of-use\u00a0assets" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r366", "r368" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted Average Discount Rate Percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r365", "r368" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted Average Remaining Lease Term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeAxis": { "auth_ref": [ "r203", "r330", "r331", "r333" ], "lang": { "en-us": { "role": { "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock.", "label": "Option Indexed to Issuer's Equity, Type [Axis]" } } }, "localname": "OptionIndexedToIssuersEquityTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.", "label": "Option Indexed to Issuer's Equity, Type [Domain]" } } }, "localname": "OptionIndexedToIssuersEquityTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r2", "r323" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "verboseLabel": "Description of Business and Organization" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganization1" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 4.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "verboseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r23", "r376" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax": { "auth_ref": [ "r38", "r39" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax", "terseLabel": "Unrealized loss on available-for-sale securities", "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax, Total", "verboseLabel": "Unrealized loss on available-for-sale securities" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r58" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited2": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other expense, net", "totalLabel": "Other Nonoperating Income (Expense), Total" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r22", "r165" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPrepaidAndOtherCurrentAssetsDetail": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other Prepaid Expense, Current", "verboseLabel": "Other prepaid expenses and other assets" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPrepaidAndOtherCurrentAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PaidInKindInterest": { "auth_ref": [ "r68" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Paid-in-Kind Interest", "terseLabel": "Non-cash\u00a0interest expense" } } }, "localname": "PaidInKindInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "terseLabel": "Payment of stock issuance costs", "verboseLabel": "Payments of stock issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r59" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Cash paid for property and equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "auth_ref": [ "r60" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Payments to Acquire Short-Term Investments", "negatedLabel": "Cash paid for purchase of short-term investments", "terseLabel": "Cash paid for purchase of short-term investments" } } }, "localname": "PaymentsToAcquireShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r284", "r285", "r286", "r287", "r288" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationFairValueOfOurCommonStockToBeIssuedUnderTheEsppDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitsActivityDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityUnderThe2021PlanDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheUnvestedCommonStockDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r284", "r285", "r286", "r287", "r288" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationFairValueOfOurCommonStockToBeIssuedUnderTheEsppDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitsActivityDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityUnderThe2021PlanDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheUnvestedCommonStockDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r14", "r212" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred Stock, Par or Stated Value Per Share", "verboseLabel": "Preferred stock par or stated value per share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred Stock, Shares Authorized", "verboseLabel": "Preferred stock shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r14", "r212" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred Stock, Shares Issued", "totalLabel": "Preferred Stock, Shares Issued, Total" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "terseLabel": "Preferred Stock, Shares Outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r24" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 }, "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPrepaidAndOtherCurrentAssetsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets", "verboseLabel": "Total prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPrepaidAndOtherCurrentAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current [Abstract]" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r4", "r164", "r165" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPrepaidAndOtherCurrentAssetsDetail": { "order": 0.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "verboseLabel": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPrepaidAndOtherCurrentAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r61" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering", "verboseLabel": "Proceeds from issuance of initial public offering" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r61" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from the issuance of common stock", "verboseLabel": "Proceeds from issuance of common stock, net" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "auth_ref": [ "r61" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.", "label": "Proceeds from Issuance of Convertible Preferred Stock", "terseLabel": "Proceeds from issuance of Series B redeemable convertible preferred shares, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": { "auth_ref": [ "r61" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.", "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock", "terseLabel": "Proceeds from redeemable convertible preferred stock" } } }, "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock": { "auth_ref": [ "r62" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash inflow from repayment of loans for purchasing common stock.", "label": "Proceeds from Repayment of Loans to Purchase Common Stock", "verboseLabel": "Proceeds from issuance of common stock upon ESPP purchase" } } }, "localname": "ProceedsFromRepaymentOfLoansToPurchaseCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r44", "r46", "r51", "r64", "r79", "r85", "r93", "r94", "r125", "r126", "r129", "r130", "r132", "r151", "r185", "r186", "r187", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r312", "r315", "r317", "r321", "r322", "r337", "r348", "r435" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited2": { "order": 0.0, "parentTag": "dawn_NetIncomeLossAvailableToCommonStockholdersBasicNotAffectingCumulativeLosses", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss and comprehensive loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersStockholdersDetail", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r169" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r8", "r167" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentDetail": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "terseLabel": "Property and equipment, gross", "totalLabel": "Property, Plant and Equipment, Gross, Total" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r169", "r376", "r440", "r446" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "terseLabel": "Property and equipment, net", "totalLabel": "Property, and equipment, net", "verboseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentOtherTypesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.", "label": "Property, Plant and Equipment, Other Types [Member]", "terseLabel": "Other Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentOtherTypesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r169" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "verboseLabel": "Schedule of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r167" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.", "label": "Redeemable Convertible Preferred Stock [Member]", "terseLabel": "Convertible preferred shares [Member]", "verboseLabel": "Redeemable convertible preferred shares" } } }, "localname": "RedeemableConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic" ], "xbrltype": "domainItemType" }, "us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity.", "label": "Redeemable Noncontrolling Interest, by Legal Entity [Table]" } } }, "localname": "RedeemableNoncontrollingInterestByLegalEntityTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount": { "auth_ref": [ "r206", "r207", "r208", "r209" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "As of the reporting date, the carrying amount of noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. The noncontrolling interest holder's ownership (or holders' ownership) may be in the form of preferred shares (regardless of class), preferred partnership units (regardless of class), preferential membership interests, or any other form of preferred equity regardless of investee entity legal form.", "label": "Redeemable Noncontrolling Interest, Equity, Preferred, Carrying Amount", "terseLabel": "Redeemable convertible preferred shares, no par value; no shares authorized, issued and outstanding at September 30, 2021; 22,851,257 shares authorized, issued and outstanding at December 31, 2020", "verboseLabel": "Carrying Value" } } }, "localname": "RedeemableNoncontrollingInterestEquityPreferredCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesSummaryOfSeriesARedeemableConvertiblePreferredSharesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RedeemableNoncontrollingInterestLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Redeemable Noncontrolling Interest [Line Items]" } } }, "localname": "RedeemableNoncontrollingInterestLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RedeemablePreferredStockDividends": { "auth_ref": [ "r96", "r229", "r237" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited2": { "order": 2.0, "parentTag": "dawn_NetIncomeLossAvailableToCommonStockholdersBasicNotAffectingCumulativeLosses", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Dividends paid to preferred stock holders that is redeemable solely at the option of the issuer.", "label": "Redeemable Preferred Stock Dividends", "negatedLabel": "Exchange of redeemable noncontrolling interest shares-deemed dividend", "terseLabel": "Exchange of redeemable noncontrolling interest shares-deemed dividend" } } }, "localname": "RedeemablePreferredStockDividends", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r250", "r371", "r372" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r250", "r371", "r372", "r373" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r250", "r371", "r373", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": { "auth_ref": [ "r166" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.", "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off", "terseLabel": "Acquired\u00a0in-process\u00a0research and development assets" } } }, "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r305", "r412", "r477" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited2": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development", "totalLabel": "Research and Development Expense, Total" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfSharestockbasedCompensationExpenseRecordedInTheAccompanyingCondensedConsolidatedStatementsOfOperatio", "http://www.dayonebio.com/20220630/taxonomy/role/SignificantAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesOfAvailableforsaleMarketableSecuritiesDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementSummaryOfCompanysFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitsActivityDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheUnvestedCommonStockDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails", "http://www.dayonebio.com/20220630/taxonomy/role/NetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesHaveBeenExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r17", "r237", "r376", "r444", "r459", "r461" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "verboseLabel": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r82", "r83", "r84", "r86", "r92", "r94", "r152", "r297", "r298", "r299", "r306", "r307", "r335", "r456", "r458" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "verboseLabel": "Accumulated Deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r364", "r368" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Lease liability obtained in exchange for right-of-use asset" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "verboseLabel": "Schedule of Accrued expenses and other current liabilities" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/NetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesHaveBeenExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Summary of Outstanding Potentially Dilutive Securities Have Been Excluded From Calculation of Diluted Net Loss Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/NetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.", "label": "Schedule of Cash and Cash Equivalents [Table]" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/SignificantAgreementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r105" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Summary of Basic and Diluted Net Loss Per Share Attributable to Common Shareholders/Stockholders" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/NetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r289", "r300" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfSharestockbasedCompensationExpenseRecordedInTheAccompanyingCondensedConsolidatedStatementsOfOperatio" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Share/Stock-based Compensation Expense Recorded in The Accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r338", "r339" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "verboseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.", "label": "Schedule of Nonvested Share Activity [Table Text Block]", "terseLabel": "Summary of The Unvested Common Stock" } } }, "localname": "ScheduleOfNonvestedShareActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r169" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r256", "r258", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r284", "r285", "r286", "r287", "r288" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationFairValueOfOurCommonStockToBeIssuedUnderTheEsppDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitsActivityDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityUnderThe2021PlanDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheIncentiveSharesActivityDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheUnvestedCommonStockDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Summary of Fair Value of The Incentive Shares Estimated Using An Option Pricing Model" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r12", "r14", "r15", "r77", "r113", "r114", "r204", "r210", "r211", "r212", "r213", "r214", "r215", "r217", "r221", "r227", "r229", "r230", "r231", "r232", "r234", "r235", "r236", "r237" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in restricted stock units (RSUs).", "label": "Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]", "terseLabel": "Summary of The Unvested Common Stock", "verboseLabel": "Summary of Restricted Stock Units Activity Under the 2021 Plan" } } }, "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecurityDeposit": { "auth_ref": [ "r10" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.", "label": "Security Deposit", "terseLabel": "Security Deposit" } } }, "localname": "SecurityDeposit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Share based compensation by share based payment arrangement term of vesting" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Number of Shares, Forfeited", "negatedTerseLabel": "Forfeiture" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitsActivityDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheIncentiveSharesActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value, Forfeited", "verboseLabel": "Forfeiture" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitsActivityDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheIncentiveSharesActivityDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheUnvestedCommonStockDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Number of Shares, Granted", "verboseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitsActivityDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheIncentiveSharesActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Grant date fair value", "verboseLabel": "Weighted Average Grant Date Fair Value, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitsActivityDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheIncentiveSharesActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r273", "r274" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested restricted stock at June 30, 2022", "periodStartLabel": "Number of Shares, Beginning balance", "terseLabel": "Unvested restricted stock at March 31, 2022" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitsActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r273", "r274" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted Average Grant Date Fair Value Per Share, Ending Balance", "periodStartLabel": "Weighted Average Grant Date Fair Value Per Share, Beginning Balance", "terseLabel": "Unvested restricted stock as of December 31, 2021", "verboseLabel": "Unvested restricted stock Grant fair value at March 31, 2022" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitsActivityDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheUnvestedCommonStockDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitsActivityDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheUnvestedCommonStockDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested", "verboseLabel": "Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitsActivityDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheUnvestedCommonStockDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price", "terseLabel": "Participating threshold" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": { "auth_ref": [ "r286" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Payments", "verboseLabel": "Share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield", "verboseLabel": "Share based compensation by share based payment award fair value assumptions dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationFairValueOfOurCommonStockToBeIssuedUnderTheEsppDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Volatility", "verboseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationFairValueOfOurCommonStockToBeIssuedUnderTheEsppDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationFairValueOfOurCommonStockToBeIssuedUnderTheEsppDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationFairValueOfOurCommonStockToBeIssuedUnderTheEsppDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitsActivityDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityUnderThe2021PlanDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheIncentiveSharesActivityDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheUnvestedCommonStockDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Share based compensation by share based payment arrangment number of shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable at June 30, 2022" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityUnderThe2021PlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeiture", "terseLabel": "Forfeiture" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityUnderThe2021PlanDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheUnvestedCommonStockDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total", "verboseLabel": "Share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted", "verboseLabel": "Share based compensation by share based payment arrangement non vested options granted during the period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityUnderThe2021PlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted", "verboseLabel": "Share based compensation by share based payment arrangement non vested options granted during the period weighted average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r296" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "negatedLabel": "Outstanding at March 31, 2022, Aggregate Intrinsic Value", "terseLabel": "Outstanding at June 30, 2022, Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityUnderThe2021PlanDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r264", "r265" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of Shares, Ending Balance", "periodStartLabel": "Number of Shares, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityUnderThe2021PlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r264", "r265" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price Per Share, Ending Balance", "periodStartLabel": "Weighted Average Exercise Price Per Share, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityUnderThe2021PlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Exercisable at June 30, 2022" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityUnderThe2021PlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r281" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Total fair value of options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum", "terseLabel": "Additional number of common stock shares reserved for future issuance as percentage of common stock shares outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Description of modification of award under share-based payment arrangement. Includes, but is not limited to, terms for expiration date, vesting rights and exercise price.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Plan Modification, Description and Terms", "terseLabel": "Description of modification of award under share-based payment arrangement" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r284", "r285", "r286", "r287", "r288" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitsActivityDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheIncentiveSharesActivityDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheUnvestedCommonStockDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeiture" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityUnderThe2021PlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityUnderThe2021PlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost": { "auth_ref": [ "r293" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The excess of the fair value of the modified award over the fair value of the award immediately before the modification.", "label": "Share-Based Goods and Nonemployee Services Transaction, Modification of Terms, Incremental Compensation Cost", "terseLabel": "Total incremental compensation cost" } } }, "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Common share fair value" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Percentage of vesting of share-based compensation awards" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Time to liquidity (in years)", "verboseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationFairValueOfOurCommonStockToBeIssuedUnderTheEsppDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r296" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "negatedLabel": "Exercisable at March 31, 2022, Aggregate Intrinsic Value", "terseLabel": "Exercisable at June 30, 2022, Aggregate Intrinsic Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityUnderThe2021PlanDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-Average Remaining Contractual Term, Exercisable at June 30, 2022" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityUnderThe2021PlanDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares", "periodEndLabel": "Number of Shares, Ending balance", "periodStartLabel": "Unvested restricted stock at December 31, 2021", "terseLabel": "Unvested restricted stock at December 31, 2021" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitsActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-Average Remaining Contractual Term, Outstanding at June 30, 2022" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityUnderThe2021PlanDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average period expected to be recognized" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares", "verboseLabel": "Share-based compensation arrangement by share-based payment award, options, vested, number of shares" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "verboseLabel": "Shares issued, price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending Balance (In shares)", "periodStartLabel": "Beginning Balance (In shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r76", "r81" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r12", "r14", "r15", "r77", "r79", "r98", "r99", "r100", "r103", "r105", "r113", "r114", "r115", "r151", "r185", "r189", "r190", "r191", "r194", "r195", "r212", "r213", "r217", "r221", "r229", "r348", "r483" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "verboseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.dayonebio.com/20220630/taxonomy/role/CoverPage", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesSummaryOfSeriesARedeemableConvertiblePreferredSharesDetail", "http://www.dayonebio.com/20220630/taxonomy/role/SignificantAgreementsAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic", "http://www.dayonebio.com/20220630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r33", "r49", "r50", "r51", "r82", "r83", "r84", "r86", "r92", "r94", "r112", "r152", "r229", "r237", "r297", "r298", "r299", "r306", "r307", "r335", "r350", "r351", "r352", "r353", "r354", "r355", "r370", "r456", "r457", "r458" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails", "http://www.dayonebio.com/20220630/taxonomy/role/SignificantAgreementsAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic1" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "verboseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic1" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "verboseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r82", "r83", "r84", "r112", "r413" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "verboseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic1" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r32", "r198", "r229", "r230", "r237" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "verboseLabel": "Issuance of Series B redeemable convertible preferred shares for cash, net of issuance costs, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/SignificantAgreementsAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "auth_ref": [ "r14", "r15", "r229", "r230", "r237" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Stock Issued During Period, Shares, Conversion of Units", "terseLabel": "Conversion of redeemable convertible preferred, common, and incentive shares into common stock (In shares)", "verboseLabel": "Stock issued during period, shares, conversion of units" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.", "label": "Stock Issued During Period, Shares, Employee Benefit Plan", "terseLabel": "Issuance of incentive shares" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan": { "auth_ref": [ "r14", "r15", "r229", "r237", "r303" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.", "label": "Stock Issued During Period, Shares, Employee Stock Ownership Plan", "terseLabel": "Stock Issued During Period, Shares, Employee Stock Ownership Plan" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r14", "r15", "r229", "r237" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of shares pursuant to Employee Stock Purchase Plan, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Stock issued during period, shares, issued for services", "verboseLabel": "Cancellations of incentive shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r14", "r15", "r229", "r237" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of incentive shares", "verboseLabel": "Common stock issued in IPO, net of issuance costs of $16,995 (In shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/SignificantAgreementsAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares (or other type of equity) forfeited during the period.", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited", "terseLabel": "Unvested stock forfeiture" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "auth_ref": [ "r33", "r229", "r237" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Stock Issued During Period, Value, Conversion of Units", "terseLabel": "Conversion of redeemable convertible preferred, common, and incentive shares into common stock , Value" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r14", "r15", "r229", "r237" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of shares pursuant to Employee Stock Purchase Plan, Amount" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r14", "r15", "r229", "r237" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Common stock issued in IPO, net of issuance costs of $16,995", "verboseLabel": "Stock Issued During Period, Value, New Issues" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/SignificantAgreementsAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r15", "r19", "r20", "r79", "r135", "r151", "r348", "r376" ], "calculation": { "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredSharesRedeemableNoncontrollingInterestAndStockholdersEquityMembersDefic" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity/members' (deficit)" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r78", "r213", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r225", "r226", "r228", "r237", "r239", "r334" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Common Stock" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureCommonStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplit": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.", "label": "Stockholders' Equity Note, Stock Split", "verboseLabel": "Stockholders' equity note, stock split" } } }, "localname": "StockholdersEquityNoteStockSplit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r356", "r378" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r356", "r378" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r356", "r378" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r356", "r378" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r377", "r379" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureSubsequentEvent" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Items" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureBalanceSheetItems" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosures of noncash activities" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityByClassOfStockTable": { "auth_ref": [ "r6", "r205" ], "lang": { "en-us": { "role": { "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.", "label": "Temporary Equity, by Class of Stock [Table]" } } }, "localname": "TemporaryEquityByClassOfStockTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesSummaryOfSeriesARedeemableConvertiblePreferredSharesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Temporary Equity Disclosure [Abstract]" } } }, "localname": "TemporaryEquityDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityDividendsAdjustment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends).", "label": "Temporary Equity, Dividends, Adjustment", "negatedLabel": "Exchange of redeemable noncontrolling interest shares - deemed dividend" } } }, "localname": "TemporaryEquityDividendsAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersStockholdersDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Temporary Equity [Line Items]" } } }, "localname": "TemporaryEquityLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesSummaryOfSeriesARedeemableConvertiblePreferredSharesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityLiquidationPreference": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Liquidation Preference", "terseLabel": "Liquidation Value" } } }, "localname": "TemporaryEquityLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesSummaryOfSeriesARedeemableConvertiblePreferredSharesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "auth_ref": [ "r6", "r205" ], "lang": { "en-us": { "role": { "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.", "label": "Temporary Equity, Par or Stated Value Per Share", "terseLabel": "Temporary Equity, Par or Stated Value Per Share" } } }, "localname": "TemporaryEquityParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesAuthorized": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Authorized", "terseLabel": "Temporary Equity, Shares Authorized", "verboseLabel": "Shares Authorized" } } }, "localname": "TemporaryEquitySharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesSummaryOfSeriesARedeemableConvertiblePreferredSharesDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Issued", "terseLabel": "Temporary Equity, Shares Issued", "verboseLabel": "Shares Issued" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesSummaryOfSeriesARedeemableConvertiblePreferredSharesDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Outstanding", "terseLabel": "Temporary Equity, Shares Outstanding", "verboseLabel": "Shares Outstanding" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail", "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesSummaryOfSeriesARedeemableConvertiblePreferredSharesDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesSubscribedButUnissued": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Amount of a new issue of securities classified as temporary equity that are allocated to investors for them to buy. When securities are sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the securities to the investor until it receives the entire proceeds. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Subscribed but Unissued", "terseLabel": "Temporary equity shares subscribed but not issued" } } }, "localname": "TemporaryEquitySharesSubscribedButUnissued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_TenantImprovements": { "auth_ref": [ "r448" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.", "label": "Tenant Improvements", "terseLabel": "Tenant improvement allowances receivable" } } }, "localname": "TenantImprovements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/CommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r144", "r145", "r147", "r148", "r149", "r199", "r227", "r332", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r483", "r484", "r485", "r486", "r487", "r488", "r489" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "http://www.dayonebio.com/20220630/taxonomy/role/SignificantAgreementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Government Corporations and Agencies Securities [Member]", "terseLabel": "U.S. government agency securities [Member]" } } }, "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementSummaryOfCompanysFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r80", "r243", "r251", "r436" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. treasury securities [Member]" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails", "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureRecurringFairValueMeasurementSummaryOfCompanysFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r116", "r117", "r119", "r120", "r121", "r122", "r123" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "verboseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r284", "r285", "r286", "r287", "r288" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r284", "r285", "r286", "r287", "r288" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r97", "r105" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "verboseLabel": "Weighted-average number of common shares used in computing net loss per share, Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersStockholdersDetail", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r95", "r105" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted Average Number of Shares Outstanding, Basic", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "verboseLabel": "Weighted-average number of common shares used in computing net loss per share, basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dayonebio.com/20220630/taxonomy/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersStockholdersDetail", "http://www.dayonebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r111": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r175": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r182": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907419&loc=d3e10037-110241" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907907&loc=d3e13051-110250" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL6757479-112611" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "63", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=126970277&loc=d3e23176-110880" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(12)(c)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(16)(c)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "14", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "15", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r239": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r253": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/subtopic&trid=2235116" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "40", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=109244457&loc=d3e16649-113920" }, "r304": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r311": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "https://asc.fasb.org/topic&trid=5833765" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r323": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90193-114008" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90198-114008" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123408481&loc=SL77919106-209958" }, "r37": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "https://asc.fasb.org/topic&trid=2122208" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r379": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(f))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r478": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r479": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r480": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r481": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r482": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r483": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r484": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r485": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r486": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r487": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r488": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r489": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r490": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r491": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.19)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r81": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" } }, "version": "2.1" }